US panel to discuss imaging products for Alzheimer’s diagnosis
This article was originally published in Clinica
The US FDA's peripheral and central nervous system drugs advisory panel will meet on October 23 to discuss the clinical development of radionuclide imaging products for the detection of amyloid to assist in the diagnosis of Alzheimer’s disease. Written submissions can be made to the contact person on or before October 8 2008.
You may also be interested in...
The US healthcare reform proposals signed into law on 23 March include requirements on medical device companies to reveal payments or gifts they make to doctors. Peter Rixon takes a closer look at what the reforms’ “sunshine” provisions actually mean
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in the coming weeks.
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in early May.